MOHAMMAD AZHAR KAMAL

Dr. MOHAMMAD AZHAR KAMAL

Royal College of Surgeons in Ireland - Bahrain, Al Muḩarraq, Bahrain
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Cell
Verified
Journal Article
Closed access
DKDhiraj Kumar
Dhiraj Kumar
LNLekha Nath
Lekha Nath
MKMOHAMMAD AZHAR KAMAL
MOHAMMAD AZHAR KAMAL
AVAnkur Varshney
Ankur Varshney
AJAvinash Jain
Avinash Jain
KRKanury V.S. Rao
Kanury V.S. Rao

15 June 2016 in Bioinformation
Verified
Journal Article
Open access
SAShazia Ali
Shazia Ali
MRMahmood Rasool
Mahmood Rasool
HCHani Chaoudhry
Hani Chaoudhry
PPPeter Pushparaj
Peter Pushparaj
PJParkash Jha
Parkash Jha
MJMohammad Sarwar Jamal
Mohammad Sarwar Jamal
Breast cancer is one of the most common cancers in women around the globe Tamoxifen is used for the last 40 years as an endocrine therapy for breast cancer. This resulted in the reduction of mortality rate by 30% and it still remains one of the most effective therapies against breast cancer. However, resistance against tamoxifen is still one of the major hurdles in the effective management of breast cancer. Intense research has been conducted in the past decade to further explore its resistance mechanism, but still a lot of research will be needed to effectively alleviate this problem. Several biochemical factors and molecular pathways, such as the modulation of ER signaling, upregulation of growth factors had been observed as key factors for tamoxifen resistance (TR). After, initial therapy of five to ten years, breast cancer patients develops resistance towards this drug. The resistance leads to the development of other cancers like uterine cancer. Here, we briefly explore all the molecular events related to tamoxifen resistance and focus on its mechanism of action as well as other pharmacological approaches to better its beneficial effects in the treatment of breast carcinoma.

16 April 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SSSania Shabbir
Sania Shabbir
EKEmaan Khurram
Emaan Khurram
VMVedhika Sathya Moorthi
Vedhika Sathya Moorthi
YEYoussef Tamer Hassan Eissa
Youssef Tamer Hassan Eissa
MKMOHAMMAD AZHAR KAMAL
MOHAMMAD AZHAR KAMAL
ABAlexandra E. Butler
Alexandra E. Butler
Polycystic ovary syndrome (PCOS) is a metabolic-reproductive-endocrine disorder that, while having a genetic component, is known to have a complex multifactorial etiology. As PCOS is a diagnosis of exclusion, standardized criteria have been developed for its diagnosis. The general consensus is that hyperandrogenism is the primary feature of PCOS and is associated with an array of physiological dysfunctions; excess androgens, for example, have been correlated with cytokine hypersecretion, adipocyte proliferation, and signaling pathway dysregulation. Another key feature of PCOS is insulin resistance, resulting in aberrant glucose and fatty acid metabolism. Additionally, the immune system plays a key role in PCOS. Hyperandrogenism stimulates some immune cells while it inhibits others, thereby disrupting the normal balance of immune cells and creating a state of chronic inflammation. This low-grade inflammation could contribute to infertility since it induces ovarian dysfunction. This dysregulated immune response in PCOS exhibits autoimmunity characteristics that require further investigation. This review paper examines the relationship between androgens and the immune response and how their malfunction contributes to PCOS.

31 January 2023 in Plants
Verified
Journal Article
Open access
PDF file
MBMudasir Ahmad Bhat
Mudasir Ahmad Bhat
Awdhesh Kumar MishraAwdhesh Kumar Mishra
Awdhesh Kumar Mishra
SJSaima Jan
Saima Jan
MBMujtaba Aamir Bhat
Mujtaba Aamir Bhat
MKMOHAMMAD AZHAR KAMAL
MOHAMMAD AZHAR KAMAL
AJArif Tasleem Jan
Arif Tasleem Jan
Plants are affected by various environmental stresses such as high or low temperatures, drought, and high salt levels, which can disrupt their normal cellular functioning and impact their growth and productivity. These stressors offer a major constraint to the morphological, physiological, and biochemical parameters; thereby attributing serious complications in the growth of crops such as rice, wheat, and corn. Considering the strategic and intricate association of soil microbiota, known as plant growth-promoting rhizobacteria (PGPR), with the plant roots, PGPR helps plants to adapt and survive under changing environmental conditions and become more resilient to stress. They aid in nutrient acquisition and regulation of water content in the soil and also play a role in regulating osmotic balance and ion homeostasis. Boosting key physiological processes, they contribute significantly to the alleviation of stress and promoting the growth and development of plants. This review examines the use of PGPR in increasing plant tolerance to different stresses, focusing on their impact on water uptake, nutrient acquisition, ion homeostasis, and osmotic balance, as well as their effects on crop yield and food security.

21 July 2011 in Blood
Verified
Journal Article
Closed access
PDF file
XNXuan-Hung Nguyen
Xuan-Hung Nguyen
PLPhilipp A. Lang
Philipp A. Lang
KLKarl S. Lang
Karl S. Lang
DADieter Adam
Dieter Adam
GFGulnar Fattakhova
Gulnar Fattakhova
KLKyeong-Hee Lee
Kyeong-Hee Lee
The regulation of cellular survival and apoptosis is of critical importance for the immune system to maintain immune homeostasis and to establish tolerance. Here, we demonstrate that the immune specific cell surface molecule Toso exhibits antiapoptotic effects on death receptor signaling by a novel regulatory mechanism involving the adaptor kinase RIP1. The antiapoptotic function of Toso depends on RIP1 ubiquitination and involves the recruitment of the death adaptor FADD to a Toso/RIP1 protein complex. In response to CD95L and TNFα, Toso promotes the activation of MAPK and NF-κB signaling pathways. Because of this relative augmentation of survival versus apoptotic signals, Toso raises the threshold for death receptor–mediated apoptosis. Our analysis of Toso-deficient mice revealed that Toso is essential for TNFα-mediated liver damage. Furthermore, the antiapoptotic function of Toso could be blocked by a Toso-specific monoclonal antibody, opening up new therapeutic prospects for the treatment of immune disorders and hematologic malignancies.

1 November 2017 in OncoImmunology
Verified
Journal Article
Closed access
ISImran Siddiqui
Imran Siddiqui
MEMarco Erreni
Marco Erreni
MKMOHAMMAD AZHAR KAMAL
MOHAMMAD AZHAR KAMAL
Porta ChiaraPorta Chiara
Porta Chiara
FMFederica Marchesi
Federica Marchesi
PAPaola Allavena
Paola Allavena
K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is a driver of progression. Oncogenic K-Ras causes the constitutive activation of NF-kB and the switch-on of an inflammatory program, which further fuels NF-kB and STAT3 activation. In this study we investigated how inflammatory pathways triggered by oncogenic K-Ras are regulated in human pancreatic cancer cells with distict epithelial or mesenchymal phenotype. Our results demonstrate that in cells with epithelial features, K-Ras driven inflammation is under the control of IL-1, while in cells undergoing EMT, is IL-1 independent. In pancreatic tumor cells with EMT phenotype, treatment with IL-1R antagonist (Anakinra) did not inhibit inflammatory cytokine production and tumor growth in mice. In these cells IL-6 is actively transcribed by the EMT transcription factor TWIST. Targeting of mesenchymal pancreatic tumors in vivo with anti-IL-6RmAb (RoActemra) successfully decreased tumor growth in immunodeficient mice, inhibited the inflammatory stroma and NF-kB-p65 and STAT3 phosphorylation in cancer cells. The results confirm that IL-1 is an important driver of inflammation in epithelial pancreatic tumors; however, tumor cells undergoing EMT will likely escape IL-1R inhibition, as IL-6 is continuously transcribed by TWIST. These findings have implications for the rational targeting of inflammatory pathways in human pancreatic cancer.